Figure 6.
Pharmacokinetics of SJP1602. (A) The plasma concentration–time profile of SJP1602 in rats. SJP1602 was administered orally (po) at a dose of 20 mg/kg and intravenously (iv) at a dose of 5 mg/kg to male SD rats. Blood concentrations of SJP1602 were measured at 0.17, 0.5, 1, 2, 4, 6, and 24 h post administration. (B) Pharmacokinetic parameters for SJP1602. The values presented are expressed as the mean ± standard deviation (SD) and the data were obtained from three independent experiments (n = 3). AUC last: area under the curve (AUC) from zero to the last measurable concentration point, Cmax: maximum concentration, Tmax: time to maximum concentration, T1/2: half-life.